Kiniksa Pharmaceuticals
KNSA
133 hedge funds and large institutions have $659M invested in Kiniksa Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 53 increasing their positions, 45 reducing their positions, and 42 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 45
7% more call options, than puts
Call options by funds: $1.34M | Put options by funds: $1.25M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9.77% less ownership
Funds ownership: 97.41% → 87.64% (-9.8%)
14% less funds holding
Funds holding: 154 → 133 (-21)
14% less capital invested
Capital invested by funds: $768M → $659M (-$109M)
48% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$13.4M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$12.5M |
| 3 |
BlackRock
New York
|
+$7.44M |
| 4 |
Millennium Management
New York
|
+$7.17M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$58.8M |
| 2 |
Goldman Sachs
New York
|
-$15M |
| 3 |
State Street
Boston,
Massachusetts
|
-$8.82M |
| 4 |
Citigroup
New York
|
-$3.43M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$2.94M |
KNSA Hedge Fund Activity: Q2 2024 in Review
133 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q2 2024, worth a combined $659M — down 14% from $768M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of KNSA and 22 opened new positions — a net loss of 20 holders — while 45 trimmed existing stakes and 53 added.
The largest buyer was Morgan Stanley, adding an estimated $13.4M. The largest seller was Vanguard Group, exiting entirely with an estimated $58.8M sold.
- 133 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q2 2024, down from 154 in Q1 2024.
- Funds reported $659M of Kiniksa Pharmaceuticals stock for Q2 2024, down 14% quarter-over-quarter.
- 22 funds opened new Kiniksa Pharmaceuticals positions in Q2 2024 and 42 closed out, a net change of -20 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q2 2024 was Morgan Stanley, an estimated $13.4M added.
- The largest Kiniksa Pharmaceuticals seller in Q2 2024 was Vanguard Group, an estimated $58.8M sold.
Based on aggregated 13F filings for Q2 2024.